Patient Care Online

Semaglutide May Reduce Alzheimer’s Risk in Adults with T2D: Daily Dose

Agitation is the most common disabling neuropsychiatric symptom experienced by individuals with Alzheimer dementia; Grossberg explains how common in this short interview.

The Most Common Bleeding Disorder in Your Patients Could be Hiding in Plain Sight

Your daily dose of the clinical news you may have missed.

By Charles Nakar, MD

Semaglutide 2.4 mg Reduces Risk for Hospitalization for Any Cause in Adults with CVD, Obesity

von Willebrand disease affects up to 1% of the population yet diagnosis is delayed an average of 16 years after onset of symptoms, especially in women.

ObesityWeek 2024: Viking Therapeutics Presents New Positive Data from VK2735 Obesity Program

ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.

Semaglutide 2.4 mg: Shows Superior Improvement in Liver Fibrosis, MASH Resolution in Pivotal Phase 3 Trial

Results from the VENTURE phase 2 trial and a phase I oral formulation study found that VK2735, a dual GLP-1 and GIP receptor agonist, demonstrated promise in treating obesity.

The RSV Vaccine Population was Narrowed for Good Reason, says Robert Hopkins, Jr, MD, Medical Director of the NFID

Novo Nordisk announced the topline findings from the pivotal ESSENCE trial and intends to file applications in early 2025 with US and EU regulators.

Metabolic Bariatric Surgery Takes a Backseat as GLP-1RA Use Soars, According to New Research

ACIP recommendations for the most appropriate older population for the RSV vaccine has shifted and the NFID medical director explains why.

Metabolic Bariatric Surgery Takes a Backseat as GLP-1RA Use Soars / Semaglutide, liraglutide injections / Image credit: ©silukstockimages/AdobeStock

FDA Approves New Treatment for Uncomplicated UTIs: Daily Dose

Clinicians should continue to monitor trade-offs between pharmacologic and surgical management of obesity, researchers said.

GoodRx, Opill Team Up on OTC Delivery Program for Contraceptive

Your daily dose of the clinical news you may have missed.

By Lauren Massaro

November 2nd 2024

The new e-commerce partnership expands access to Opill by allowing direct delivery of the contraceptive to consumers' homes without a prescription.

Eisai Announces Submission of Rolling BLA for SQ Autoinjector-Delivered Lecanemab image credit dementia ©Billion Photos/Shutterstock.com

Eisai Announces Completion of Rolling BLA for SQ Autoinjector-Delivered Lecanemab

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

The autoinjector delivers a weekly maintenance dose of 360 mg lecanemab for individuals who have completed biweekly treatment initiation by IV infusion.

Dermatologist Mona Shahriari, MD, Talks Nonsteroidal Topicals for Atopic Dermatitis

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose

There are 3 classes of nonsteroidal topical therapies for atopic dermatitis that target the specific underlying pathophysiology of the skin disease. Shahriari provides a primer.

Greatest Increase in Mortality from Early-Onset Colorectal Cancer Seen Among Youngest US Adults

Your daily dose of the clinical news you may have missed.

Mortality from Early Onset Colorectal Cancer Increasing Most Among Youngest Americans image credit Rutgers New Jersey Medical School

Worst States for Health Care in the US: 2024

ACG: Mortality associated with both early- and late-stage EO-CRC rose most significantly among young adults aged 20 to 44 years between 2000 and 2022, new research reveals.

GLP-1RAs Reduce the Risk of Early-Onset Colorectal Cancer in Adults with T2D

Get a quick look at the US worst states for health care ranked using a composite score that included measures of cost, access, and outcomes.

New Phase 3 Data Suggest Benefits of Early Lecanemab Initiation on Alzheimer Disease Progression, Support Long-Term Safety

ACG 2024: New study results indicate GLP-1 RAs have a potentially protective role to play in combating EO-CRC, the incidence of which is notably rising worldwide.

New Data Support Lecanemab Long-Term Dosing in Alzheimer Disease and Benefit In Earliest Stage / image credit ©Lightspring/Shuttestock.com

Roche Amyloid Plasma Panel for Alzheimer Disease Demonstrates Negative Predictive Value of 96%, Company Announced

New data from phase 3 Clarity AD OLE trial show sustained treatment benefit among participants with low baseline tau and brain amyloid with no new safety signals.

Social, Racial Disparities in Flu, COVID-19, RSV Vaccine Uptake: Daily Dose

CATD 2024: The Elecsys plasma panel also demonstrated high sensitivity and specificity for AD, building strong evidence for streamlined early disease detection.

Atopic Dermatitis: Final ADORING 3 Open-Label Extension Trial Findings with Tapinarof Cream, 1% Announced

Your daily dose of the clinical news you may have missed.

Atopic Dermatitis: Final ADORING 3 Open-Lael Extension Trial Findings with Tapinarof 1% Announced / image credit atopic dermatitis concept ©New Africa/stock.adobe.com

Early Detection of Skin Cancer Will Keep Getting Better Using AI-Based Technology: Expert Perspective

Over 80% of participants, (2 to 17 y/o) achieved clear or almost clear skin during the 48-week trial, and treatment-free intervals lasted more than 2 months.

Early Detection of Skin Cancer Will Keep Getting Better Using New Technology: Expert Perspective

Topical Steroids Still Have a Role in Atopic Dermatitis Treatment, But It is Limited Expert Says

Rebecca Hartman, MD, MHP, assistant professor of dermatology at Brigham and Women's Hospital and Harvard Medical School, reviews new point-of-care detection technology.